SCHEMBL2068236

SCHEMBL2068236

Nc1ccccc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
RECQL P46063 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KEAP1 Q14145 2/20 0.56
IL1RN P18510 1/20 0.55
ERAP1 Q9NZ08 1/20 0.55
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
PKM P14618 1/20 0.52
HTR6 P50406 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
MAPT P10636 2/20 0.50
PIK3CG P48736 1/20 0.50
G6PD P11413 1/20 0.50
NFKBIA P25963 1/20 0.50
AGTR1 P30556 1/20 0.50
METAP2 P50579 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30737452 1.00 ALDH1A1 (0.58) ALDH1A1RECQLSMN1; SMN2KEAP1IL1RN
Hydrochloric Acid SCHEMBL29885455 0.98 ALDH1A1 (0.56) ALDH1A1RECQLSMN1; SMN2KEAP1IL1RN
SCHEMBL30737499 0.85 ALDH1A1 (0.66) ALDH1A1KMT2AMEN1SLC40A1GAA
SCHEMBL6561655 0.85 MEN1 (0.66) KEAP1KMT2AMEN1PKMGLO1
SCHEMBL398000 0.85 LMNA (0.70) ALDH1A1SMN1; SMN2KEAP1CA1CA2
SCHEMBL30737629 0.85 MEN1 (0.66) KEAP1KMT2AMEN1PKMGLO1
SCHEMBL4184006 0.85 ALDH1A1 (0.66) ALDH1A1KMT2AMEN1SLC40A1GAA
SCHEMBL15145878 0.85 MEN1 (0.52) ALDH1A1SMN1; SMN2CA1CA2CA9
SCHEMBL2067538 0.85 ALDH1A1 (0.68) ALDH1A1RECQLSMN1; SMN2KEAP1IL1RN
SCHEMBL5595259 0.85 PGR (0.59) ALDH1A1SMN1; SMN2KEAP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037309-B2 Compound, agent and composition for the suppression of cancer growth VECTOR VITALE IP LLC (US) 2024-07-16 US disclosed
US-12037309-B2 Compound, agent and composition for the suppression of cancer growth VECTOR VITALE IP LLC (US) 2024-07-16 US disclosed
US-12036238-B2 Method of treating parkinson's and other neurodegenerative diseases VECTOR VITALE IP LLC (US) 2024-07-16 US disclosed
US-12036238-B2 Method of treating parkinson's and other neurodegenerative diseases VECTOR VITALE IP LLC (US) 2024-07-16 US disclosed
US-11827588-B2 Compound, agent and composition for the suppression of cancer growth VECTOR VITALE IP LLC (US) 2023-11-28 US disclosed
US-11827588-B2 Compound, agent and composition for the suppression of cancer growth VECTOR VITALE IP LLC (US) 2023-11-28 US disclosed
US-11779597-B2 Method of treating Parkinson's and other neurodegenerative diseases VECTOR VITALE IP LLC (US) 2023-10-10 US disclosed
US-11779597-B2 Method of treating Parkinson's and other neurodegenerative diseases VECTOR VITALE IP LLC (US) 2023-10-10 US disclosed
US-20230210894-A1 RUBIDIUM AND/OR ZINC COMPOUNDS FOR TREATING PARKINSON'S AND OTHER NEURODEGENERATIVE DISEASES VECTOR VITALE IP LLC (US) 2023-07-06 US disclosed
US-20230210894-A1 RUBIDIUM AND/OR ZINC COMPOUNDS FOR TREATING PARKINSON'S AND OTHER NEURODEGENERATIVE DISEASES VECTOR VITALE IP LLC (US) 2023-07-06 US disclosed
US-7294716-B2 Process for preparing isomerically pure prodrugs of proton pump inhibitors ALLERGAN, INC. (US) 2007-11-13 US disclosed
EP-1818325-A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION (US) 2007-08-15 EP disclosed
US-20070142639-A1 Process for production of amines TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-06-21 US disclosed
EP-1381590-B1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORP (US) 2007-06-20 EP disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 US disclosed
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2007-01-25 US disclosed
US-6180796-B1 TUBULIN POLYMERIZATION INHIBITORS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2001-01-30 US disclosed
US-5760196-A PRINTING AND DYEING HYDROPHOBIC FIBERS OF POLYESTERS FOR COLORFASTNESS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-06-02 US disclosed
EP-0727464-A2 Monoazo compounds and methods for dyeing or printing hydrophobic fiber materials using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-08-21 EP disclosed
US-4241079-A ANTHELMINTICS AND FUNGICIDES ROHM AND HAAS COMPANY (US) 1980-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021494-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands CCR1, ACKR3, CXCR1 ALDH1A1 1019/4885RECQL 4150/4885SMN1; SMN2 4403/4885
US-20230210894-A1 RUBIDIUM AND/OR ZINC COMPOUNDS FOR TREATING PARKINSON'S AND OTHER NEURODEGENERATIVE DISEASES SOD1, SNCA, SLC39A11 ALDH1A1 751/4885RECQL 1450/4885SMN1; SMN2 124/4885
US-20070142639-A1 Process for production of amines SMS, CCNT1, PEAK1 ALDH1A1 1001/4885RECQL 3395/4885SMN1; SMN2 2249/4885
US-12036238-B2 Method of treating parkinson's and other neurodegenerative diseases SOD1, SNCA, PARK7 ALDH1A1 911/4885RECQL 1237/4885SMN1; SMN2 77/4885
US-12037309-B2 Compound, agent and composition for the suppression of cancer growth RPL32, MKI67, RPL41 ALDH1A1 1061/4885RECQL 1407/4885SMN1; SMN2 3668/4885
US-11779597-B2 Method of treating Parkinson's and other neurodegenerative diseases SOD1, SNCA, PARK7 ALDH1A1 911/4885RECQL 1237/4885SMN1; SMN2 77/4885
US-11827588-B2 Compound, agent and composition for the suppression of cancer growth RPL32, MKI67, RPL41 ALDH1A1 1061/4885RECQL 1407/4885SMN1; SMN2 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.